Insider · CIK 0001724310

Watts Ryan J.

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001724310

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-12	DNLIDenali Therapeutics Inc.G Gift	Director, President and CEO	GGift	−32.2K sh	—	—	2,120,384
2026-01-06	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−35.2K sh	$16.50	−$581K	296,833
2026-01-03	DNLIDenali Therapeutics Inc.A Award	Director, President and CEO	AAward	+79K sh	—	—	332,031
2026-01-03	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director, President and CEO	AAward	+237K sh	—	—	236,880
2025-09-03	DNLIDenali Therapeutics Inc.G Gift	Director, President and CEO	GGift	−50K sh	—	—	2,152,604
2025-07-09	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+455K sh	$0.68	+$310K	708,353
2025-07-09	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+40K sh	$5.28	+$211K	748,353
2025-07-09	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−495K sh	$15.00	−$7.43M	253,071
2025-07-09	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−455K sh	—	—	622,809
2025-07-09	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−40K sh	—	—	20,369
2025-01-07	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−7,650 sh	$20.81	−$159K	253,071
2025-01-06	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−29.3K sh	$20.22	−$592K	260,721
2025-01-03	DNLIDenali Therapeutics Inc.A Award	Director, President and CEO	AAward	+54.2K sh	—	—	289,987
2025-01-03	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director, President and CEO	AAward	+163K sh	—	—	162,540
2024-10-18	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+40K sh	$0.68	+$27.2K	275,807
2024-10-18	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−40K sh	$27.69	−$1.11M	235,807
2024-10-18	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−40K sh	—	—	1,078,091
2024-08-20	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−2,260 sh	$23.79	−$53.8K	235,807
2024-03-29	DNLIDenali Therapeutics Inc.G Gift	Director, President and CEO	GGift	−40K sh	—	—	2,202,604
2024-02-13	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−9,589 sh	$17.29	−$166K	238,067
2024-01-09	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−7,818 sh	$19.78	−$155K	2,268,363
2024-01-05	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−17.5K sh	$19.43	−$340K	2,276,181
2024-01-03	DNLIDenali Therapeutics Inc.A Award	Director, President and CEO	AAward	+89.5K sh	—	—	272,957
2024-01-03	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director, President and CEO	AAward	+269K sh	—	—	268,560
2023-08-21	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−2,309 sh	$22.59	−$52.2K	2,242,604
2023-08-10	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+2,526 sh	$0.68	+$1,717.68	2,242,439
2023-08-10	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−2,526 sh	$25.03	−$63.2K	2,239,913
2023-08-10	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−2,526 sh	—	—	1,118,091
2023-06-16	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+50K sh	$0.68	+$34K	2,289,913
2023-06-16	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−50K sh	$31.40	−$1.57M	2,239,913
2023-06-16	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−50K sh	—	—	1,120,617
2023-04-21	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+24.8K sh	$0.68	+$16.9K	2,264,713
2023-04-21	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−24.8K sh	$25.15	−$624K	2,239,913
2023-04-21	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−24.8K sh	—	—	1,170,617
2023-04-20	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+200 sh	$0.68	+$136	2,240,113
2023-04-20	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−200 sh	$25.00	−$5,000	2,239,913
2023-04-20	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−200 sh	—	—	1,195,417
2023-02-13	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−8,815 sh	$30.09	−$265K	2,239,913
2023-02-13	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+25K sh	$0.68	+$17K	2,264,913
2023-02-13	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−25K sh	$30.08	−$752K	2,239,913
2023-02-13	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−25K sh	—	—	1,195,617
2023-02-10	DNLIDenali Therapeutics Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+25K sh	$0.68	+$17K	2,254,031
2023-02-10	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−25K sh	$29.10	−$728K	2,229,031
2023-02-10	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−25K sh	—	—	1,220,617
2023-02-09	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−3,433 sh	$30.59	−$105K	2,229,031
2023-01-05	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−4,800 sh	$28.44	−$137K	2,223,664
2023-01-04	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−5,029 sh	$28.73	−$144K	2,213,464
2023-01-03	DNLIDenali Therapeutics Inc.A Award	Director, President and CEO	AAward	+82.2K sh	—	—	231,934
2023-01-03	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director, President and CEO	AAward	+247K sh	—	—	246,720
2022-08-19	DNLIDenali Therapeutics Inc.S Sale	Director, President and CEO	SSale	−2,404 sh	$33.22	−$79.9K	2,202,993

Recent filings

Accepted (ET)
Aug 144
Watts Ryan J.0001724310-26-000007
SEC(opens sec.gov)
Jan 84
Watts Ryan J.0001724310-26-000004
SEC(opens sec.gov)
Jan 54
Watts Ryan J.0001724310-26-000001
SEC(opens sec.gov)
Sep 54
Watts Ryan J.0001724310-25-000005
SEC(opens sec.gov)
Jul 114
Watts Ryan J.0001714899-25-000149
SEC(opens sec.gov)
Jan 84
Watts Ryan J.0001714899-25-000049
SEC(opens sec.gov)
Jan 74
Watts Ryan J.0001714899-25-000028
SEC(opens sec.gov)
Oct 224
Watts Ryan J.0001714899-24-000206
SEC(opens sec.gov)
Aug 224
Watts Ryan J.0001714899-24-000197
SEC(opens sec.gov)
Mar 294
Watts Ryan J.0001714899-24-000097
SEC(opens sec.gov)
Feb 154
Watts Ryan J.0001714899-24-000061
SEC(opens sec.gov)

Companies

Denali Therapeutics Inc.Director, President and CEODNLI

Address

C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD.

SOUTH SAN FRANCISCO, CA, 94080